UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 23, 2012 (January 20, 2012)
ALEXZA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 000-51820 | 77-0567768 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
Alexza Pharmaceuticals, Inc. 2091 Stierlin Court |
94043 | |||
(Address of principal executive offices) | (Zip Code) |
Registrants telephone number, including area code: (650) 944-7000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 Other Events
Item 8.01. Other Events.
On January 23, 2012, Alexza Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for ADASUVE (Staccato® loxapine). In a notice received from the FDA, the Prescription Drug User Fee Act (PDUFA) date for the ADASUVE NDA has been extended from February 4, 2012, to May 4, 2012. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.
Section 9 Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description | |
99.1 | Press Release titled Alexza Announces Extension of the ADASUVE PDUFA Goal Date by Three Months, dated January 23, 2012. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALEXZA PHARMACEUTICALS, INC. | ||||||
Date: January 23, 2012 | ||||||
By: | /s/ Thomas B. King | |||||
Thomas B. King President and Chief Executive Officer |
INDEX TO EXHIBITS
Exhibit Number |
Description | |
99.1 | Press Release titled Alexza Announces Extension of the ADASUVE PDUFA Goal Date by Three Months, dated January 23, 2012. |
Exhibit 99.1
NEWS RELEASEfor immediate release
Alexza Announces Extension of the ADASUVE PDUFA
Goal Date by Three Months
New PDUFA Goal Date is May 4, 2012
Mountain View, California January 23, 2012 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for ADASUVE (Staccato® loxapine). In a notice received from the FDA, the Prescription Drug User Fee Act (PDUFA) date for the ADASUVE NDA has been extended from February 4, 2012, to May 4, 2012.
The FDA notified Alexza that its January 10, 2012 submission to the NDA, updating the proposed Risk Evaluation and Mitigation Strategy (REMS) program, has been designated as a major amendment. The FDA exercised its option to extend the PDUFA goal date to provide time to complete the review when a sponsor submits materials the FDA considers a major amendment to an NDA within three months of the PDUFA goal date. Alexza has submitted this amendment to the NDA, among others, to address topics discussed during the December 12, 2011 Psychopharmacologic Drugs Advisory Committee meeting on the ADASUVE application.
We continue to believe that we are on a pathway to gain approval of ADASUVE in the United States, stated Thomas B. King, President and Chief Executive Officer of Alexza Pharmaceuticals. We appreciate the efforts of the FDA to complete their review of our NDA and we will continue to support the continued review of the NDA.
About ADASUVE (Staccato loxapine) and the Staccato System
ADASUVE is an anti-agitation product candidate that combines Alexzas proprietary Staccato system with loxapine, an antipsychotic currently available in the U.S. as an oral formulation for the management of schizophrenia. The Staccato system is a hand-held, single-dose inhaler that delivers a medication comparable to intravenous administration, but with greater ease, patient comfort and convenience. Click here to see an animation of how the Staccato system works. In clinical studies, ADASUVE has shown an onset of effect in 10 minutes of dosing, which is the first time point measured in the Phase 3 clinical studies. The ADASUVE NDA contains efficacy and safety data from more than 1,600 patients and subjects, who have been studied in thirteen different clinical trials.
Page 1 of 3
About Alexza Pharmaceuticals, Inc.
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexzas technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.
ADASUVE (Staccato loxapine) is Alexzas lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder. Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009. In October 2010, the Company received a Complete Response Letter from the FDA regarding the application. The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011. The ADASUVE NDA was resubmitted in August 2011, completed an advisory committee meeting in December 2011, received a notice of extension of the Prescription Drug User Fee Act (PDUFA) goal date in January 2012, and has a new Prescription Drug User Fee Act (PDUFA) goal date of May 4, 2012.
In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer Internacional, S.A. Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexzas partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.
For more information about Alexza, the Staccato system technology or the Companys development programs, please visit www.alexza.com.
Safe Harbor Statement
This press release contains forward-looking statements that involve significant risks and uncertainties. Any statement describing the Companys expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Companys capital to support the Companys operations, the Companys ability to raise additional funds and the potential terms of such potential financings, the potential of the
Page 2 of 3
Companys ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDAs review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Common-wealth of Independent States countries. The Companys forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexzas business are described in additional detail in the Companys Annual Report on Form 10-K for the year ended December 31, 2010, and the Companys other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
CONTACTS: | Thomas B. King | |
President and CEO | ||
650.944.7634 | ||
tking@alexza.com |
Page 3 of 3
-'Y"V$K=EK,7&O
M+6-L2T#+MTQU@/)T1EVSX_E L4^QG;*W4,[1N5104]4^IY;90'DA
M:O%Y?F`^6#R3AQE$W5;Q_C!85N6B:K7J9A#*%A1964(GI\Q3NNEBLJZ%SSZ):T/9329&7$3F,((2XY0`*YXTO'S3[77KU4^%_&JLW.
MIRS&=K5G@L0TR*G(*9BUTW,=)QDDQBD'+1ZQ<)E.FH0P&*8`$!`>NN]_
]A,C*>,5A%2VW6BK99"&@X%^7,F4B"!JSX2GG`.B>.%